Considering the anti-inflammatory effect of A3 receptor engagement in RA patients by modulating TNF-α and NF-κB, A3 agonists for the therapy of RA, as well as for psoriasis, are currently tested in clinical trials or have been evaluated already. The gene discussed is NFKB1; the disease is rheumatoid arthritis.